Rapport Therapeutics (RAPP)

• Market cap: $1.18B
• 1 day: -1.43%
• 5 days: -3.66%
• 1 month: -6.36%
• 3 months: 69.64%
• 6 months: 142.89%
• Year to date: 34.58%
• 1 year: 16.03%
• 5 years: 18.99%
• 10 years: 18.99%
• Sector: Healthcare
• Industry: Biotechnology

About: Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.

Employees: 69